LETTERS TO THE EDITOR N-Glycosylation of apolipoprotein A1 in cardiovascular diseases

摘要

A very interesting paper by Cubedo et al has been recently published ''Glycoproteome of human Apo A-I: N- and O-glycosylated forms are increased in acute myocardial infarction patients,'' which significantly contributes to our field in the clinical application of pro-teomics in cardiovascular diseases. The authors demonstrated (among other results) that both the N- and O-glycosylation of apolipoprotein A1 (apoAl) changed in patient plasma during the first 3 days after an acute myocardial infarction (AMI) event. In our recent study, we observed high molecular weight forms of apoAl (hm-apoAl) of approximately 50 kDa in the plasma samples of patients with AMI, unstable angina pectoris (UAP), and stable angina pectoris (SAP). These hm-apoAl were detected using 1- and 2-dimensional Western blot analysis and seemed to occur at different levels among the studied cohorts. The apoAl N-glycosylated forms described by Cubedo et al in AMI patients seem to correspond to those observed in our published work; therefore, we decided to verify this assumption and to estimate their presence in other cardiovascular diseases, SAP, and UAP, in addition to AMI.